Alzamend Neuro is trading 5.66% up at $1.68, despite no identified company-specific announcement explaining the September 1, 2026 rise.
- Recent company news concerns August presentation acceptances, including Neuroscience 2026 poster data announced August 20.
- The move diverges from broader weakness, with biotechnology down 4.24% and major U.S. indexes lower.
- The catalyst remains unclear.